International Cancer Conference Journal最新文献

{"title":"Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer.","authors":"Megumi Tokunaga,&nbsp;Shuichi Nawata,&nbsp;Takayuki Komoto,&nbsp;Rei Mathuura,&nbsp;Daisuke Ichikura,&nbsp;Toru Watanabe,&nbsp;Tadanori Sasaki","doi":"10.1007/s13691-022-00576-5","DOIUrl":"https://doi.org/10.1007/s13691-022-00576-5","url":null,"abstract":"<p><p>The standard of care for ovarian cancer chemotherapy is paclitaxel-carboplatin. In Stage III and Stage IV patients, the addition of bevacizumab has been reported to be effective, and bevacizumab combined with paclitaxel-carboplatin and bevacizumab combined with docetaxel-carboplatin are used. Patients who received bevacizumab combined with docetaxel-carboplatin experienced a high incidence of skin hardening followed by peeling. In patients treated with bevacizumab combined with docetaxel-carboplatin, we experienced a high incidence of post-sclerotic peeling of the skin, a symptom that is rarely seen with paclitaxel-carboplatin (TC), docetaxel-carboplatin (DC), or bevacizumab combined with paclitaxel-carboplatin, and has been reported in a few cases. Therefore, we investigated the actual situation of skin desquamation caused by bevacizumab combined with docetaxel-carboplatin. Thirty-one patients were included in the study, and their age (mean ± SD) was 62.9 ± 9.0. The breakdown of treatment was as follows: TC in nine patients, bevacizumab combined with paclitaxel-carboplatin in ten patients, DC in six patients, and bevacizumab combined with docetaxel-carboplatin in six patients. No number of patients with TC or bevacizumab combined with paclitaxel-carboplatin showed skin desquamation. One for DC, and five for bevacizumab combined with docetaxel-carboplatin. The five patients treated with bevacizumab combined with docetaxel-carboplatin improved with topical steroids and moisturizers, but symptoms repeatedly appeared after each course. Skin desquamation was more frequent in bevacizumab combined with docetaxel-carboplatin.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"49-52"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solitary pulmonary capillary hemangioma mimicking a preinvasive malignant lesion in an asymptomatic middle-aged female patient.","authors":"Yasuyuki Kanamoto,&nbsp;Hitoshi Dejima,&nbsp;Yuichi Saito,&nbsp;Toshihiro Haga,&nbsp;Tomohiro Watanabe,&nbsp;Yoshikane Yamauchi,&nbsp;Yuko Sasajima,&nbsp;Koji Saito,&nbsp;Masafumi Kawamura,&nbsp;Yukinori Sakao","doi":"10.1007/s13691-022-00570-x","DOIUrl":"https://doi.org/10.1007/s13691-022-00570-x","url":null,"abstract":"<p><p>Pulmonary capillary hemangiomatosis (PCH) is a rare disease characterized by a proliferation of capillaries in the alveolar septa, bronchial and venous walls, pleura, and regional lymph nodes. However, the etiology of the disease remains unknown due to its rarity. Therefore, we present a case of a solitary PCH lesion without symptoms in a 38-year-old female patient. According to computed tomography, she was diagnosed with lung carcinoma, indicated by a tiny nodule with ground-glass opacity detected in her right upper lung. However, no other lesions were detected on systemic examination. Consequently, partial lung resection was conducted, since the lesion was suspected of lung adenocarcinoma. Pathologic results showed that the thick alveolar septa were caused by capillary growth without cellular atypia and hardly any infiltration of inflammatory cells. Finally, we diagnosed the pulmonary lesion as PCH, although solitary PCH has previously been reported in a few case reports. Therefore, further case studies are essential to clarify the causes of PCH.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"14-18"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807707/pdf/13691_2022_Article_570.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9926140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perianal Bowen's disease treated with radiotherapy preserving anal function with a unique skin reaction considered as 'tumoritis'.","authors":"Takahiro Iwai,&nbsp;Toshiyuki Imagumbai,&nbsp;Shun Okabayashi,&nbsp;Ryo Ashida,&nbsp;Takamasa Mitsuyoshi,&nbsp;Yukimasa Tai,&nbsp;Toshihiko Matsumoto,&nbsp;Daisuke Yamashita,&nbsp;Tohru Nagano,&nbsp;Masaki Kokubo","doi":"10.1007/s13691-022-00574-7","DOIUrl":"https://doi.org/10.1007/s13691-022-00574-7","url":null,"abstract":"<p><p>Bowen's disease (BD) is a form of intraepidermal squamous cell carcinoma (SCC), and it occasionally occurs on the perianal site. BD is often treated with surgical excision; however, sometimes surgical excision for perianal BD cannot preserve anal function. We report the case of a 72-year-old man presenting with perianal pain and BD. He was treated with Radiotherapy (RT) and preserved his normal anal sphincter function without any recurrence or late adverse event. Moreover, we observed the unique skin reaction called 'tumoritis', which is characterized by mucosal inflammation. Tumoritis indicates the true extent of the tumor and evaluating the tumor or lesion size based on the extent of tumoritis when performing RT is important.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"41-45"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807712/pdf/13691_2022_Article_574.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10078610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma.","authors":"Shunji Sano,&nbsp;Yoh Asahi,&nbsp;Toshiya Kamiyama,&nbsp;Tatsuhiko Kakisaka,&nbsp;Tatsuya Orimo,&nbsp;Akihisa Nagatsu,&nbsp;Takeshi Aiyama,&nbsp;Keizo Kazui,&nbsp;Hiroki Shomura,&nbsp;Shinya Ueki,&nbsp;Yuzuru Sakamoto,&nbsp;Chisato Shirakawa,&nbsp;Hirofumi Kamachi,&nbsp;Hirokazu Sugino,&nbsp;Tomoko Mitsuhashi,&nbsp;Akinobu Taketomi","doi":"10.1007/s13691-022-00567-6","DOIUrl":"https://doi.org/10.1007/s13691-022-00567-6","url":null,"abstract":"<p><p>Although systemic treatment for hepatocellular carcinoma has advanced after the development of tyrosine kinase inhibitors such as sorafenib and lenvatinib, the effectiveness of a single tyrosine kinase inhibitor in survival extension of unresectable hepatocellular carcinoma is limited to a few months. Therefore, novel treatment options are required for unresectable hepatocellular carcinomas, including those with multiple lung metastases. This case report describes a hepatocellular carcinoma patient with a recurrence of multiple lung metastases, which was successfully treated with conversion pneumonectomy after treatment with tyrosine kinase inhibitors. A 79-year-old man underwent right hepatectomy for hepatocellular carcinoma, along with removal of the tumor thrombus in the inferior vena cava. Multiple lung metastases were detected 4 months after hepatectomy. Treatment with tyrosine kinase inhibitors, mainly lenvatinib, resulted in complete remission of the lung metastases, except for one lesion in segment 3 of the right lung which gradually enlarged. Twenty-three months after hepatectomy, partial resection of the right lung was performed using video-assisted thoracic surgery for this residual lesion in the right lung. The patient remained disease-free for 11 months after conversion pneumonectomy, without any adjuvant therapies. This is the first case report of multiple lung metastases originating from hepatocellular carcinoma which were successfully treated with conversion pneumonectomy after treatment with tyrosine kinase inhibitors. Conversion pneumonectomy after systemic therapy with tyrosine kinase inhibitors should be considered as a treatment strategy for patients with unresectable multiple lung metastases from hepatocellular carcinomas.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"7-13"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807693/pdf/13691_2022_Article_567.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax.","authors":"Hirofumi Ohmura,&nbsp;Takaaki Masuda,&nbsp;Koshi Mimori,&nbsp;Eishi Baba,&nbsp;Takahiko Horiuchi","doi":"10.1007/s13691-022-00572-9","DOIUrl":"https://doi.org/10.1007/s13691-022-00572-9","url":null,"abstract":"<p><p>Here, we present a 59-year-old female with recurrent malignant phyllodes tumor with multiple lung and lymph node metastases who developed a pneumothorax after the administration of pazopanib. The patient received pazopanib as the second-line chemotherapy. After 2.5 months of the therapy, computed tomography (CT) showed a decrease in the sizes and cavitation of lung lesions; however, a left pneumothorax was newly observed. It was difficult to distinguish the pneumothorax by upright chest X-ray. Typical symptom or physical finding of pneumothorax, such as dyspnea, chest pain or decreased breath sound was not observed. As the pneumothorax was small and asymptomatic, the administration of pazopanib was discontinued and follow-up chest X-ray and CT were performed. After 1 week, CT showed an improvement in the pneumothorax. Chemotherapy was switched to eribulin; however, a rapid increase in sizes of lung lesions was observed after the first administration of eribulin, pazopanib was reintroduced. Careful follow-up by chest X-ray and CT was performed and the pneumothorax has not recurred.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"31-35"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807701/pdf/13691_2022_Article_572.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report.","authors":"Yu Miyama,&nbsp;Kent Kanao,&nbsp;Kousuke Uranishi,&nbsp;Masataka Hirasaki,&nbsp;Masanori Yasuda","doi":"10.1007/s13691-022-00568-5","DOIUrl":"https://doi.org/10.1007/s13691-022-00568-5","url":null,"abstract":"<p><p>In advanced urothelial carcinoma (UC), approximately 20% of patients respond to pembrolizumab, an anti-programmed cell death-1 (PD-1) antibody. Herein, we reported a single case of UC showing coexistence of sarcomatoid subtype and glandular differentiation. Notably, only glandular differentiation was recurrent, probably progressive, and metastatic, which showed complete response to pembrolizumab. An 80-year-old woman presented with hematuria and dysuria, and an intra-vesical tumor was detected on ultrasound. Transurethral resections (TUR) were performed three times. In the first TUR, a sub-pedunculated tumor and a flat lesion were closely but independently located. Pathologically, the sub-pedunculated tumor was an invasive UC, sarcomatoid subtype. Meanwhile, the flat lesion was invasive UC with glandular differentiation. Despite the second and the additional TUR, the tumor was growing and a lymph node metastasis was detected. The third TUR specimen showed UC with glandular differentiation, and a positive PD-L1 expression as well as high density CD8-positive lymphocytic cells infiltration were observed. Pembrolizumab was administered for four courses after terminating the chemotherapy. The CT scan revealed shrinkage of both primary tumor and metastases. Cystectomy and lymph nodes dissection were performed, and no residual carcinoma was detected. The therapeutic effect was regarded as pathological complete response. Pembrolizumab could be effective for special subtype or divergent differentiation of UC, particularly in an event of an 'immune hot' tumor.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-022-00568-5.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 1","pages":"24-30"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807710/pdf/13691_2022_Article_568.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10317191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of paraovarian tumor of borderline malignancy with decrease of apparent diffusion coefficient value and marked 18F-fluorodeoxyglucose accumulation.","authors":"Akimi Yoshida, Koji Yamanoi, Asuka Okunomiya, Yusuke Sagae, Masumi Sunada, Mana Taki, Masayo Ukita, Yasuhisa Kurata, Yuki Himoto, Aki Kido, Akihito Horie, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai","doi":"10.1007/s13691-022-00590-7","DOIUrl":"10.1007/s13691-022-00590-7","url":null,"abstract":"<p><p>Para-ovarian cysts are occasionally encountered in clinical practice; however, malignant tumors derived from them are rare. Due to its rarity, the characteristic imaging findings of para-ovarian tumors with borderline malignancy (PTBM) are largely unknown. Herein, we report a case of PTBM, along with imaging findings. A 37-year-old woman came to our department with a suspected malignant adnexal tumor. Pelvic contrast-enhanced magnetic resonance imaging (MRI) revealed a solid part within the cystic tumor with a decrease in the apparent diffusion coefficient (ADC) value (1.16 × 10^-3 mm²/s). We also performed Positron Emission Tomography-MRI and showed a strong accumulation of 18F-fluorodeoxyglucose (FDG) in the solid part (SUVmax = 14.8). In addition, the tumor appeared to develop independently of the ovary. Because tumor was derived from para-ovarian cyst, we suspected PTBM preoperatively and planned fertility sparing treatment. Pathological examination revealed a serous borderline tumor and PTBM was confirmed. PTBM can have unique imaging characteristics, including a low ADC value and high FDG accumulation. When a tumor appears to develop from para-ovarian cysts, borderline malignancy can be suspected, even if imaging findings suggest malignant potential.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"126-130"},"PeriodicalIF":0.7,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9093602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical resection of primary leiomyosarcoma of retro-hepatic inferior vena cava extending from bilateral renal veins across the diaphragm.","authors":"Yohei Inoguchi, Koji Hatano, Taigo Kato, Atsunari Kawashima, Toyofumi Abe, Shinichiro Fukuhara, Motohide Uemura, Hiroshi Kiuchi, Ryoichi Imamura, Norio Nonomura","doi":"10.1007/s13691-022-00589-0","DOIUrl":"10.1007/s13691-022-00589-0","url":null,"abstract":"<p><p>Vascular leiomyosarcoma of the inferior vena cava is a rare malignant soft tissue tumor that requires surgical treatment to prevent tumor-related symptoms such as pulmonary embolism and Budd-Chiari syndrome. However, a treatment strategy for surgical resection of advanced cases has not yet been determined. This report describes the case of advanced leiomyosarcoma of the inferior vena cava that was successfully treated with surgery and subsequent chemotherapy. A 44-year-old man was found to have a 12 × 10 cm retroperitoneal tumor on computed tomography. The tumor originated in the inferior vena cava and extended beyond the diaphragm into the renal vein. The surgical plan was determined in joint consultation with the multidisciplinary team. It was safely resected and the inferior vena cava was closed caudal to the porta hepatis without a synthetic graft. The tumor was diagnosed as leiomyosarcoma. Doxorubicin, followed by pazopanib were administered as treatment for metastatic disease. Eighteen months after the surgery, the patient's performance status was maintained.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"115-119"},"PeriodicalIF":0.7,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9086355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab.","authors":"Sho Nambara, Yoshihisa Sakaguchi, Yasuo Tsuda, Kensuke Kudou, Eiji Kusumoto, Rintaro Yoshida, Tetsuya Kusumoto, Koji Ikejiri","doi":"10.1007/s13691-022-00582-7","DOIUrl":"10.1007/s13691-022-00582-7","url":null,"abstract":"<p><p>Primary malignant melanoma of the esophagus is a rare disease with a severely poor prognosis. Here, we report a patient with primary malignant melanoma of the esophagus surviving without recurrence after surgery and adjuvant therapy with nivolumab. The patient was a 60-year-old female with dysphagia. Esophagogastroscopy showed an elevated dark brown tumor in the lower thoracic esophagus. A histological examination of the biopsy revealed human melanoma black 45 and melan-A positivity. The patient was diagnosed with primary malignant melanoma of the esophagus and was treated with radical esophagectomy. As postoperative treatment, the patient was given nivolumab (240 mg/body) every 2 weeks. Although bilateral pneumothorax occurred after 2 courses, she recovered after chest drainage. Nivolumab treatment is still ongoing over 1 year after the surgery, and the patient has survived without recurrence. We conclude that nivolumab is an optimal option as a postoperative adjuvant treatment for PMME.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"100-103"},"PeriodicalIF":0.7,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9093600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver metastases of a neuroendocrine tumor arising from a tailgut cyst treated with interventional locoregional therapies: a case report and review of the literature on recurrent cases.","authors":"Kosuke Fujimoto, Fumikazu Koyama, Hiroyuki Kuge, Shinsaku Obara, Yosuke Iwasa, Takeshi Takei, Tadataka Takagi, Tomomi Sadamitsu, Suzuka Harada, Tomoko Uchiyama, Chiho Ohbayashi, Hideyuki Nishiofuku, Toshihiro Tanaka, Masayuki Sho","doi":"10.1007/s13691-022-00587-2","DOIUrl":"10.1007/s13691-022-00587-2","url":null,"abstract":"<p><p>A tailgut cyst is a rare, developmental cyst occurring in the presacral space. Although primarily benign, malignant transformation is a possible complication. Herein, we report a case of liver metastases after resection of a neuroendocrine tumor (NET) arising from a tailgut cyst. A 53-year-old woman underwent surgery for a presacral cystic lesion with nodules in the cyst wall. The tumor was diagnosed as a Grade 2 NET arising from a tailgut cyst. Thirty-eight months after surgery, multiple liver metastases were identified. The liver metastases were controlled with transcatheter arterial embolization and ablation therapy. The patient has survived for 51 months after the recurrence. Several NETs derived from tailgut cysts have been previously reported. According to our literature review, the proportion of Grade 2 tumors in NETs derived from tailgut cysts was 38.5%, and four of the 5 cases of Grade 2 NETs (80%) relapsed, while all eight cases of Grade 1 NETs did not relapse. Grade 2 NET may be a high-risk group for recurrence in NETs arising from tailgut cysts. The percentage of Grade 2 NETs in tailgut cysts was higher than that of rectal NETs, but lower than that of midgut NETs. To the best of our knowledge, this is the first case of liver metastases of a neuroendocrine tumor arising from a tailgut cyst that was treated with interventional locoregional therapies, and the first report to describe about the degree of malignancy of neuroendocrine tumors originating from tailgut cysts in terms of the percentage of Grade 2 NETs.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"93-99"},"PeriodicalIF":0.7,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9086357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}